- Home
- GNS vs GRML Comparison
GNS vs GRML Comparison
Compare GNS & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNS | GRML |
|---|---|---|
| Founded | 2002 | N/A |
| Country | Singapore | United States |
| Employees | N/A | 5 |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 34.9M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GNS | GRML |
|---|---|---|
| Price | $0.15 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.9M | ★ 7.7M |
| Earning Date | 03-09-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $156.26 | N/A |
| Revenue Next Year | $35.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.16 |
| 52 Week High | $1.28 | $0.55 |
Technical Indicators
Market Signals| Indicator | GNS | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 44.53 |
| Support Level | N/A | $0.16 |
| Resistance Level | $0.23 | $0.30 |
| Average True Range (ATR) | 0.01 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 18.45 | 31.13 |
Price Performance
Historical ComparisonAbout GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.
About GRML Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.